We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
Read MoreHide Full Article
Cronos Group (CRON - Free Report) is scheduled to report first-quarter results on May 8, before market open.
The company missed earnings expectations by 75% in the last reported quarter. Over the trailing four quarters, it surpassed earnings estimates on three occasions and missed in the other, the average positive surprise being 477.08%.
Cronos is a global cannabinoid company. Revenues soared 71% year over year in the last reported quarter, primarily driven by an increase in the volume of products sold in the Rest of World segment and the Redwood acquisition. A similar trend is likely to have continued in the to-be-reported quarter as well.
In September 2019, the company acquired four Redwood Holding Group, LLC operating subsidiaries. The transaction has provided Cronos with a leading U.S. hemp-based products platform, including hemp-derived CBD-infused skincare and other consumer products, which are sold online and through retail and hospitality partner channels in the United States, under the brand Lord Jones.
The incremental revenues from Redwood are expected to have boosted the company’s first-quarter performance.
In December 2019, Cronos launched cannabis vaporizer devices for the Canadian adult-use market under the COVE and Spinach brands.
Meanwhile, the company decided to pause the distribution of PEACE+ hemp-derived CBD tinctures through Altria Group. Inc.’s (MO - Free Report) sales and distribution networks. Cronos will continue to evaluate other product formats and categories, which it believes will be more suitable for the PEACE+ brand in the evolving environment. An update on the same will be awaited with the results.
In the fourth quarter, Cronos began selling cannabis flower and extract products to cannabis control authorities in Alberta, Manitoba and Quebec. The addition of new territories is likely to boost performance. However, the company might have seen an adverse impact on its operational capacity or supply-chain delays in certain parts of the business in the quarter due to the COVID-19 outbreak.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Cronos this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Cronos is +7.69%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Alexion Pharmaceuticals has an Earnings ESP of +1.08% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
Cronos Group (CRON - Free Report) is scheduled to report first-quarter results on May 8, before market open.
The company missed earnings expectations by 75% in the last reported quarter. Over the trailing four quarters, it surpassed earnings estimates on three occasions and missed in the other, the average positive surprise being 477.08%.
Cronos Group Inc. Price and Consensus
Cronos Group Inc. price-consensus-chart | Cronos Group Inc. Quote
Factors in Focus
Cronos is a global cannabinoid company. Revenues soared 71% year over year in the last reported quarter, primarily driven by an increase in the volume of products sold in the Rest of World segment and the Redwood acquisition. A similar trend is likely to have continued in the to-be-reported quarter as well.
In September 2019, the company acquired four Redwood Holding Group, LLC operating subsidiaries. The transaction has provided Cronos with a leading U.S. hemp-based products platform, including hemp-derived CBD-infused skincare and other consumer products, which are sold online and through retail and hospitality partner channels in the United States, under the brand Lord Jones.
The incremental revenues from Redwood are expected to have boosted the company’s first-quarter performance.
In December 2019, Cronos launched cannabis vaporizer devices for the Canadian adult-use market under the COVE and Spinach brands.
Meanwhile, the company decided to pause the distribution of PEACE+ hemp-derived CBD tinctures through Altria Group. Inc.’s (MO - Free Report) sales and distribution networks. Cronos will continue to evaluate other product formats and categories, which it believes will be more suitable for the PEACE+ brand in the evolving environment. An update on the same will be awaited with the results.
In the fourth quarter, Cronos began selling cannabis flower and extract products to cannabis control authorities in Alberta, Manitoba and Quebec. The addition of new territories is likely to boost performance. However, the company might have seen an adverse impact on its operational capacity or supply-chain delays in certain parts of the business in the quarter due to the COVID-19 outbreak.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Cronos this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Cronos is +7.69%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Sage Therapeutics (SAGE - Free Report) has an Earnings ESP of +1.67% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alexion Pharmaceuticals has an Earnings ESP of +1.08% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>